National Cancer Centre Singapore
Some information on this page may be available only to Healthcare Professionals. Please

About

Research Trials at the National Cancer Centre Singapore   

The National Cancer Centre Singapore (NCCS) is a leading national and regional tertiary cancer centre that attends to 65 per cent of all cancer cases in the public sector in Singapore. In addition to offering world class cancer care, our clinicians work closely with our scientists who conduct robust, cutting-edge clinical and translational research with local and international collaboration.  

Clinical trials are the best way to improve treatment outcomes for cancer and NCCS is leading the way with dynamic clinical trials aimed at developing novel and innovative treatments for all cancer types. With over two decades of experience, the Clinical Trials Office of the Humphrey Oei Institute of Cancer Research has conducted more than 450 phase I to III clinical trials to date and currently oversees more than 200 ongoing trials at NCCS.  

Clinical trials at NCCS are focused on evaluating the effectiveness of novel molecular targeted agents and next generation immunotherapy approaches, while implementing the use of new technologies and digital medicine tools. Biostatistical research and epidemiological surveys are also conducted to assess real-time patient experience. NCCS has multiple active bio-pharma and bio-tech collaborations for clinical and translational research, creating a pipeline to take effective treatments to market and give new hope to individuals with cancer.     

For more information, please visit: www.nccs.com.sg   

Media

YouTube Linkedin Facebook Twitter

Oncology services

General Oncology Services

  • Supportive and Palliative Care
  • Radiation Oncology
  • Oncologic Imaging
  • Psychosocial Oncology
  • Nursing
  • Surgical Oncology
  • Medical Oncology

Oncology treatment

  • Surgery
  • Local/Regional therapies
  • Immunotherapy
  • Targeted therapy
  • Chemotherapy
  • Hormonal therapy

Common tumour types seen:

All solid tumors and hematologic cancers

Specialist Services

  • Cancer Genetics
  • Comprehensive Liver Cancer
  • Cancer Education and Information Services

Branches

1

National Cancer Centre Singapore

11 Hospital Crescent, Singapore 169610

Mon—Fri: 8:30 AM — 5:30 PM

Sat: 8:30 AM — 12:30 PM

Closed on Sunday and Public Holidays

Ongoing trials at National Cancer Centre Singapore

72 trials shown

Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole

This is a phase II study testing the combination of pembrolizumab with lenvatinib, a multi-kinase inhibitor that has activity against vascular endothelial growth factor receptors 1

Study number:
NCT05286437
Cohorts:
1
Study phase:
2
Overall status:
Recruiting
Study type:
Targeted therapy, Hormonal therapy

A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma

This Phase 1/ 2 study is a multicenter study to evaluate the safety, tolerability and efficacy of SCG101 in subjects with hepatitis B virus-related hepatocellular carcinoma

Study number:
NCT05417932
Cohorts:
1
Study phase:
1, 2
Overall status:
Recruiting
Study type:
Immunotherapy

Novartis

Key trial

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

This is Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.

Study number:
NCT05358249
Cohorts:
3
Study phase:
1, 2
Overall status:
Recruiting
Study type:
Targeted therapy, Biomarker

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

Researchers are looking for a better way to treat people who have advanced solid tumors. Advanced solid tumors are solid cancers that may have spread to nearby tissue, lymph nodes

Study number:
NCT05537740
Cohorts:
1
Study phase:
1
Overall status:
Not yet recruiting
Study type:
Immunotherapy, Targeted therapy, Chemotherapy

Dose Escalation and Expansion Study of SAR444200 in Adult Participants With Advanced Solid Tumors

This is a single group, treatment, Phase 1/Phase 2, open label, multiple cohort, first-in-human study to evaluate safety and efficacy of SAR444200 as a monotherapy or in combinatio

Study number:
NCT05450562
Cohorts:
2
Study phase:
1, 2
Overall status:
Recruiting
Study type:
Targeted therapy

Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients

This is a multi-national, phase II, parallel-arm, double-blind, placebo-controlled, two-arm study designed to assess the efficacy and safety of SIRT-Y90 followed by atezolizumab pl

Study number:
NCT05377034
Cohorts:
1
Study phase:
2
Overall status:
Not yet recruiting
Study type:
Local/Regional therapies, Immunotherapy, Targeted therapy

Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)

The primary objective is to evaluate in participants with high-grade serous ovarian cancer (HGSOC), whether the reduction from baseline in circulating tumor DNA (ctDNA) at Cycle 3

Study number:
NCT05446870
Cohorts:
1
Study phase:
2
Overall status:
Recruiting
Study type:
Immunotherapy, Chemotherapy

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally re

Study number:
NCT05374512
Cohorts:
1
Study phase:
3
Overall status:
Recruiting
Study type:
Immunotherapy, Chemotherapy

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platinum-based chemotherapy offers li

Study number:
NCT05338970
Cohorts:
2
Study phase:
3
Overall status:
Recruiting
Study type:
Targeted therapy, Biomarker

A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer

The purpose of this study is to evaluate relatlimab in combination with nivolumab, administered as a fixed-dose combination (nivolumab-relatlimab FDC, also referred to as BMS-98621

Study number:
NCT05328908
Cohorts:
1
Study phase:
3
Overall status:
Recruiting
Study type:
Immunotherapy, Targeted therapy, Chemotherapy